Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

被引:263
|
作者
Fechtner, Robert D. [2 ]
Godfrey, David G. [3 ]
Budenz, Donald [4 ]
Stewart, Jeanette A. [1 ]
Stewart, William C. [1 ]
Jasek, Mark C. [5 ]
机构
[1] PRN Pharmaceut Res Network LLC, Dallas, TX 75240 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Ophthalmol, Newark, NJ 07103 USA
[3] Glaucoma Associates Texas, Dallas, TX USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Alcon Labs Inc, Ft Worth, TX 76101 USA
关键词
glaucoma; therapy; ocular surface disease; OSDI; prevalence; DRY EYE SYNDROME; OPHTHALMIC EMULSION; DISEASE; EFFICACY; MODERATE; SAFETY;
D O I
10.1097/ICO.0b013e3181c325b2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP) lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and SDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 +/- 15.4 vs 15.4 +/- 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 +/- 15.6 vs 15.3 +/- 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 +/- 13.1, which was significantly lower than those of patients on 2 (16.7 +/- 17.0; P = 0.007) or 3 medications (19.4 +/- 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [1] The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review
    Asiedu, Kofi
    Abu, Sampson Listowell
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2019, 31 (01): : 8 - 15
  • [2] Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy
    Gomes, Beatriz
    de Freitas Turiel, Paulo Romeu
    Marques, Fabiane Pereira
    Bernardo, Fernanda Pessoa
    Abbud Safady, Marcus Vinicius
    Freire Portes, Andre Luos
    Santhiago, Marcony Rodrigues
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2013, 76 (05) : 282 - 287
  • [3] Prevalence and description of treatment with intraocular pressure-lowering topical medications in continental France
    Delcourt, C.
    Bron, A.
    Baudouin, C.
    Denis, P.
    Nordmann, J. -P.
    Renard, J. -P.
    Rouland, J. -F.
    Sellem, E.
    Stephan, M.
    Levrat, F.
    Solesse, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2006, 29 (10): : 1098 - 1106
  • [4] Intraocular light scatter in patients on topical intraocular pressure-lowering medication
    Perez-Bartolome, Francisco
    Martinez de la Casa, Jose Maria
    Arriola-Villalobos, Pedro
    Fernandez-Perez, Cristina
    Garcia-Feijoo, Julian
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2018, 28 (06) : 652 - 661
  • [5] Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice
    Hollo, Gabor
    Topouzis, Fotis
    Fechtner, Robert D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (12) : 1737 - 1747
  • [6] Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
    Tanihara, Hidenobu
    Kakuda, Takahiko
    Sano, Tetsuro
    Kanno, Takashi
    Kurihara, Yuji
    ADVANCES IN THERAPY, 2022, 39 (04) : 1659 - 1677
  • [7] Use of Topical Intraocular Pressure-lowering Medications in the US Population: Results From the NHANES Study 1999 to 2014
    Lowry, Eugene A.
    Chansangpetch, Sunee
    Lin, Shan C.
    JOURNAL OF GLAUCOMA, 2019, 28 (09) : 772 - 776
  • [8] Ocular Surface Disease Exacerbated Glaucoma: Optimizing the Ocular Surface Improves Intraocular Pressure Control
    Batra, Ruchika
    Tailor, Rajen
    Mohamed, Shabbir
    JOURNAL OF GLAUCOMA, 2014, 23 (01) : 56 - 60
  • [9] First and second transscleral cyclophotocoagulation treatments provide similar intraocular pressure-lowering efficacy in patients with refractory glaucoma
    Enrico, Bernardi
    Marc, Toeteberg-Harms
    INTERNATIONAL OPHTHALMOLOGY, 2022, 42 (08) : 2363 - 2369
  • [10] The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension
    Costa, Vital Paulino
    Marcon, Italo Mundialino
    Galvao Filho, Roberto Pedrosa
    Santiago Malta, Roberto Freire
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2013, 76 (04) : 221 - 225